Ingredion Misses Q3 2026 Estimates as Revenue Falls 1.3% to $1.79B

Ingredion (INGR) missed estimates for the third quarter of 2026 on both revenue and adjusted EPS. Revenue was $1.79 billion, down 1.3% from a year earlier, below the $1.80 billion estimate, and adjusted EPS was $2.28, down 17% from a year earlier, below the $2.59 estimate.

Shares fell 3.5% in premarket trading as of 6:03 a.m. ET, to $94.10 from a $97.47 close.

Q3 2026 scorecard

By our calculation, revenue was $8.2 million below the estimate and adjusted EPS was $0.31 below it. The QoQ column compares with the previous quarter's revenue of $1.85 billion and adjusted EPS of $2.82. The YoY column compares with $1.82 billion and $2.75 in the same quarter a year earlier.

Track record

• EPS record. Adjusted EPS beat the estimate in 5 of the last 8 reports, including this one.
• Revenue record. Revenue beat the estimate in 1 of the last 8 reports.
• Revenue trend. Revenue over the last 5 reports, oldest first: $1.82 billion, $1.76 billion, $1.79 billion, $1.85 billion and $1.79 billion.

What to watch

• Next-quarter estimates. Consensus calls for EPS of $2.65 and revenue of $1.75 billion next quarter, based on 3 analysts.
• Revenue growth. Whether revenue stabilizes after this quarter's 1.3% decline from a year earlier to $1.79 billion.
• Estimate record. Whether Ingredion extends a record of beating EPS estimates in 5 of its last 8 reports.
• Related coverage. See our reports on Lemonade, LifeStance Health, Prestige Consumer Healthcare and GigaCloud Technology.

Sources: Results are from Ingredion's Nov. 5, 2026 quarterly report. Estimates are consensus figures. The prior-quarter and year-ago comparison figures are from Ingredion's earlier quarterly reports. Items labeled by our calculation are our own arithmetic. This article is informational only and is not investment advice.